That sounds like good news but did you have to put it in two existing threads and start a new one? If it doesn't end up any better than hydroxychloroquine your enthusiasm will look about as good as Trumps enthusiasm on that one.

Results seem promising

hydroxychloroquine looked very promising according to Trump until we found out he had a financial interest in it.

Moderna Inc
NASDAQ: MRNA
66.69 USD +2.13 (3.30%)
Closed: May 18, 8:28 AM EDT ·
Pre-market 93.51 +26.82 (40.22%)

Even if it doesn't pan out someone is going to make a lot of money on it huh?

Stock market live updates: Dow futures up 650, Moderna positive vaccine data,

Spoken like a true ignorant Trump supporter

If I may be presumptuous, you don't appear to be the type that is heavily invested in stocks or municipal bonds and such. Just like Trump, never dealing with the current situation but always speaking of better days ahead. In the mean time, address 38 million people being unemployed,m address those that are still seeking immediate help in regard to late mortgage payments, no ability to pay their rent. Has the DOW placed another meal on the tables of hungry children? Did the upswing heal the sick or raise the dead? For many, going back 4 months, nothing has changed...you know son, a 30000 DOW average while having no health insurance or a great job paying 50K a year. Six months ago having NO health insurance and working at McDonald isn't exactly my ideal to wake up any morning and sing "Happy day are here again" but a fool will attempt to state otherwise. BTW Son, I am heavily invested but what does that do for you and others?

https://www.fool.com/investing/2020/05/14/where-will-moderna-be-in-5-years.aspx

Where Will Moderna Be in 5 Years?

The stock is being boosted by the biotech's front-runner status in the race to produce a coronavirus vaccine, but where will the company be long after the pandemic?

Moderna is no stranger to the bright glare of investor attention. When the company launched its initial public offering (IPO) in December 2018, it was the largest IPO of a clinical-stage biotech in history. And before going public, it had already attracted over $2.6 billion in private equity investments, had $1.2 billion in cash, and had already established partnerships with industry heavyweights like AstraZeneca, Merck, and Vertex

One big advantage of Moderna's approach to vaccines is the speed at which the vaccine can be invented and manufactured. When COVID-19 appeared, that nimbleness was exactly what the world needed. The time from the day the sequence for the spike protein of the SARS-CoV-2 was finalized until the first participant in a phase 1 study of its vaccine candidate, mRNA-1273, was dosed was a mere 63 days. The company should be starting a phase 2 study soon, plans a phase 3 trial in early summer, and hopes for approval of the drug in 2021. The coronavirus pandemic accelerated Moderna's vaccine plans, with the U.S. Food and Drug Administration (FDA) more than willing to speed up processes to get the vaccine to the public.

Moderna's approach to developing a vaccine is the fastest one but not necessarily the best one. So far, we don't have any more evidence that an mRNA vaccine actually prevents disease than we did last year. Despite the rapid progression of clinical tests for mRNA-1273, we still haven't seen any data from the phase 1 trial yet.

The company has reported data from phase 1 trials of other mRNA vaccines it has in development for cytomegalovirus (CMV), respiratory viruses human metapneumovirus and parainfluenza type 3, and interim data from a Zika virus vaccine. Those results have been encouraging so far, but the only measures of efficacy have been blood levels of neutralizing antibodies. There is a big difference between observing an immune response and showing that vaccine prevents disease, something that can only be proved by a study with thousands of participants who are potentially exposed to the live virus.

In fact, Moderna has yet to produce data that shows that any of its 23 drug candidates can prevent or treat diseases, let alone proof strong enough for an agency approval. That's the big question mark hanging over the company, and it hasn't changed since the IPO.

It would not be unusual for a biotech stock of Moderna's growth potential to be valued at 10 to 15 times sales when it's in the commercial phase, and with today's market capitalization of $24 billion, the stock could triple or more by 2025 if the optimistic scenario above comes to pass. But with the technology still unproven, the share price could go in the other direction, too, if there are setbacks.

In the short term -- just looking ahead to next year -- I think the risks outweigh the benefits, given the expectations for the coronavirus vaccine that are now built into the stock price. But longer term, the stock is more interesting because of the potential of its mRNA platform to turn out a steady stream of new drugs. I think an investor who is willing to hold Moderna shares for five years has a reasonable chance for a big payoff, but it's not a sure thing at all.

https://www.fool.com/investing/2020/05/14/where-will-moderna-be-in-5-years.aspx

Jim Crumly
(TMFSpeyside)

May 14, 2020 at 6:16AM


10 stocks we like better than Moderna INC

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

Ongoing trials

These ongoing trials usually take several years or more. Seldom any less than that.

Stage 3 trials may occur as soon as july 2020

Ok I can see you are totally sucked in Trumps's cult and beyond hope of believing anything different.

Moderna company president stated it in a news briefing

mRNA has sped up the process

I think, everyone who wants a vaccine from Bill gates and Fouci should be first in line to get it. Those who do not want it, leave them alone. Freedom of choice is a wonderful thing.

And what is Biden's solutions?